Department of Drug Development, Nevada Cancer Institute, Las Vegas, NV, USA.
Exp Cell Res. 2010 May 15;316(9):1576-86. doi: 10.1016/j.yexcr.2010.01.012. Epub 2010 Jan 11.
The phenotypic diversity of breast carcinoma may be explained by the existence of a sub-population of breast cancer cells, endowed with stem cell-like properties and gene expression profiles, able to differentiate along different pathways. A stem cell-like population of CD44(+)CD24(-/low) breast cancer cells was originally identified using cells from metastatic pleural effusions of breast carcinoma patients. We have previously reported that upon in vitro culture as mammospheres under stem cell-like conditions, human MA-11 breast carcinoma cells acquired increased tumorigenicity and lost CD24 expression compared with the parental cell line. We now report that upon passage of MA-11 mammospheres into serum-supplemented cultures, CD24 expression was restored; the rapid increase in CD24 expression was consistent with up-regulation of the antigen, and not with in vitro selection of CD24(+) cells. In tumors derived from subcutaneous injection of MA-11 mammospheres in athymic nude mice, 76.1+/-9.7% of cells expressed CD24, vs. 0.5+/-1% in MA-11 cells dissociated from mammospheres before injection. The tumorigenicity of sorted CD44(+)CD24(-) and CD44(+)CD24(high) MA-11 cells was equal. Single cell-sorted CD24(-) and CD24(high) MA-11 gave rise in vitro to cell populations with heterogeneous CD24 expression. Also, subcutaneous tumors derived from sorted CD24(-) sub-populations and single-cell clones had levels of CD24 expression similar to the unsorted cells. To investigate whether the high expression of CD24 contributed to the tumorigenic potential of MA-11 cells, we silenced CD24 by shRNA. CD24 silencing (95%) resulted in no difference in tumorigenicity upon s.c. injection in athymic nude mice compared with mock-transduced MA-11 cells. Since CD24 silencing was maintained in vivo, our data suggest that the level of expression of CD24 is associated with but does not contribute to tumorigenicity. We then compared the molecular profile of the mammospheres with the adherent cell fraction. Gene expression profiling revealed that the increased tumorigenicity of MA-11 mammospheres was associated with changes in 10 signal transduction pathways, including MAP kinase, Notch and Wnt, and increased expression of aldehyde dehydrogenase, a cancer-initiating cell-associated marker. Our data demonstrate that (i) the level of CD24 expression is neither a stable feature of mammosphere-forming cells nor confers tumorigenic potential to MA-11 cells; (ii) cancer-initiating cell-enriched MA-11 mammospheres have activated specific signal transduction pathways, potential targets for anti-breast cancer therapy.
乳腺癌的表型多样性可以用存在一群具有干细胞样特性和基因表达谱的乳腺癌细胞来解释,这群细胞能够沿着不同的途径分化。最初是从乳腺癌患者的转移性胸腔积液中使用细胞来鉴定 CD44(+)CD24(-/低)的乳腺癌干细胞样群体。我们之前曾报道过,在类似于干细胞的条件下作为乳腺球体进行体外培养时,人 MA-11 乳腺癌细胞获得了更高的致瘤性,并失去了与亲本细胞系相比的 CD24 表达。我们现在报告说,当 MA-11 乳腺球体进入补充有血清的培养物中时,CD24 表达得到恢复;抗原的上调与 CD24(+)细胞的体外选择一致,而不是与 CD24(+)细胞的体外选择一致。在无胸腺裸鼠皮下注射 MA-11 乳腺球体衍生的肿瘤中,76.1+/-9.7%的细胞表达 CD24,而在注射前从乳腺球体分离的 MA-11 细胞中仅表达 0.5+/-1%。分选的 CD44(+)CD24(-)和 CD44(+)CD24(high)MA-11 细胞的致瘤性相等。单细胞分选的 CD24(-)和 CD24(high)MA-11 在体外产生具有异质 CD24 表达的细胞群体。此外,源自分选的 CD24(-)亚群和单细胞克隆的皮下肿瘤具有与未分选细胞相似的 CD24 表达水平。为了研究 CD24 的高表达是否有助于 MA-11 细胞的致瘤潜能,我们通过 shRNA 沉默了 CD24。与 mock 转导的 MA-11 细胞相比,CD24 沉默(95%)在无胸腺裸鼠皮下注射后对致瘤性没有影响。由于 CD24 沉默在体内得以维持,我们的数据表明 CD24 的表达水平与致瘤性相关,但不赋予致瘤性。然后,我们比较了乳腺球体与贴壁细胞部分的分子谱。基因表达谱分析显示,MA-11 乳腺球体的致瘤性增加与 10 个信号转导途径的变化有关,包括 MAP 激酶、Notch 和 Wnt,以及醛脱氢酶(一种与癌症起始细胞相关的标记物)的表达增加。我们的数据表明:(i)CD24 表达水平既不是乳腺球体形成细胞的稳定特征,也不赋予 MA-11 细胞致瘤潜能;(ii)富含癌症起始细胞的 MA-11 乳腺球体已激活特定的信号转导途径,这可能是抗乳腺癌治疗的潜在靶点。